# of Displayed Technologies: 20 / 62

Applied Category Filter (Click To Remove): Healthcare Portfolios


Categories

Apoprotein manufacturing and methods for protein purification
TS-050238 — Methods of purifying proteins that can be used in various applications such as drug delivery, bioimaging and hemolysis treatment.
Novel protein and apoprotein purification strategies are valuable tools with a wide variety of medical and research applications. While there are existing techniques for protein and apoprotein purification, some of these have flaws such as the use of harsh denaturants, highly flammable solvents, l…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Davis, Stewart

Apoprotein manufacturing and methods for protein purification
TS-050238 — Methods of purifying proteins that can be used in various applications such as drug delivery, bioimaging and hemolysis treatment.
Novel protein and apoprotein purification strategies are valuable tools with a wide variety of medical and research applications. While there are existing techniques for protein and apoprotein purification, some of these have flaws such as the use of harsh denaturants, highly flammable solvents, l…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Davis, Stewart

Apoprotein manufacturing and methods for protein purification
TS-050238 — Methods of purifying proteins that can be used in various applications such as drug delivery, bioimaging and hemolysis treatment.
Novel protein and apoprotein purification strategies are valuable tools with a wide variety of medical and research applications. While there are existing techniques for protein and apoprotein purification, some of these have flaws such as the use of harsh denaturants, highly flammable solvents, l…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Davis, Stewart

Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
  • College: College of Pharmacy
  • Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
  • Licensing Officer: Flammang, Ann Marie

The Buckeye Quit Stick: A novel support device to address the hand-to-oral cigarette habit of patients who are attempting to quit smoking
TS-050189 — A novel support device to address the hand-to-oral cigarette habits of patients who are attempting to quit smoking.
The Need Tobacco addiction is a common problem in cancer patients and more than half of newly diagnosed lung cancer patients are active smokers. Smoking can affect a patient’s surgical safety, quality of life, and cancer recovery and survival outcomes. While treatment products can successfull…
  • College: College of Nursing
  • Inventors: Both, Deborah; Eastep, Christine
  • Licensing Officer: Flammang, Ann Marie

Method for diagnosis and prognosis of Alzheimer's disease
TS-050046 — Methods using miRNAs for early Alzheimer’s Disease diagnoses and altered expression of key autophagy related proteins
The Need Alzheimer’s Disease (AD) is the most common cause of age-related dementia leading to severe and irreversible neurodegeneration and cognitive decline. Currently, AD has no cure or effective preventive approaches. Using current diagnostic techniques, AD cannot be clinically diagnosed b…
  • College: College of Medicine (COM)
  • Inventors: Amer, Amal
  • Licensing Officer: Flammang, Ann Marie

Inhibition of DGAT for the treatment of cancer
TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…
  • College: College of Medicine (COM)
  • Inventors: Guo, Deliang
  • Licensing Officer: Ezzell, Janel

A Novel Vaccine for Listeriosis Infection
TS-049471 — Listeriosis is an infectious disease caused by the bacterial pathogen Listeria monocytogenes. Although the average number of cases is moderate in the United States (1600-2500/year), listeriosis is a significant health concern due to its exceptionally high fatality rate. Indeed, listeriosis is the …
  • College: OSU Wexner Medical Center
  • Inventors: Seveau, Stephanie
  • Licensing Officer: Ezzell, Janel

Analogues of the Epipolythiodioxopiperazine Alkaloids
TS-047118 — Analogues of verticillin which have more useful drug-like properties than the verticillin parent compounds alone, including increased solubility, absorption, and stability, all while maintaining similar anticancer potency to the original compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Flammang, Ann Marie

Adoptive Transfer of Engineered Macrophages
TS-045881 — The Need Cell therapies have received recent approvals for immunomodulatory indications. Immuno-activating chimeric antigen receptor (CAR)–T cells have been developed for cancers, whereas immunosuppressive mesenchymal stromal cells (MSCs) have been approved for inflammatory bowel disease and …
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Hou, Xucheng; Zhang, Xinfu
  • Licensing Officer: Flammang, Ann Marie

Adoptive Transfer of Engineered Macrophages
TS-045881 — The Need Cell therapies have received recent approvals for immunomodulatory indications. Immuno-activating chimeric antigen receptor (CAR)–T cells have been developed for cancers, whereas immunosuppressive mesenchymal stromal cells (MSCs) have been approved for inflammatory bowel disease and …
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Hou, Xucheng; Zhang, Xinfu
  • Licensing Officer: Flammang, Ann Marie

Improved Dressing Design for Insertion Sheaths with Side Ports
TS-044969 — Dressing designed and tailored exclusively for insertion sheaths with side ports, used frequently for pulmonary artery catheters (PACs or Swan-Ganz catheters) among other intravascular devices in the hospital.
The Need Central-line associated blood stream infections (CLABSIs) are a life-threatening and extremely costly problem in hospitals around the world. When patients in the hospital have indwelling catheters such as pulmonary artery catheters, they are at an increased risk of developing such infectio…
  • College: OSU Wexner Medical Center
  • Inventors: Warren, Samantha; Thomas, Jordan
  • Licensing Officer: Flammang, Ann Marie

Biomimetic vitreous substitute with ocular drug delivery
TS-044490 — Methods and compositions for an antioxidant releasing hydrogel vitreous substitute
The vitreous humor is a fragile, transparent tissue between the lens and the retina of the eye that maintains the shape of the eye, acts as a shock absorber, and enables nutrient diffusion to ocular tissues. The vitreous also plays a key role in oxygen homeostasis. Over time, the vitreous degrades…
  • College: College of Engineering (COE)
  • Inventors: Swindle-Reilly, Katelyn; Reilly, Matthew; Tram, Nguyen "Archie"
  • Licensing Officer: Flammang, Ann Marie

Composition and method of lipid nanoparticles carrying oligonucleotides
TS-043629 — Novel lipid nanoparticles used for carrying antisense oligonucleotides with improved targeting for cancer treatment
Lung cancer is the leading cause of cancer related deaths in the US with approximately 150,000 deaths in 2017. Currently, mildly ineffective chemotherapeutics ripe with adverse side effects are the standard treatment. Antisense oligonucleotides (ASOs) are able to selectively modulate expression of…
  • College: College of Pharmacy
  • Inventors: Lee, Robert; Cheng, Xinwei "Evan"
  • Licensing Officer: Flammang, Ann Marie

A Bi-layered Capsule for Sustainable Delivery of Protein Therapeutics
TS-042858 — A biodegradable drug delivery system for the treatment of disease, especially ophthalmic diseases including age-related macular degeneration (AMD). The device will be injected and can control drug release for at least 6 months following the initial injection.
Retinal diseases can be extremely difficult to monitor once procedures have been initiated. AMD is the fourth most common causes of blindness and requires monthly injections to manage the effects of the disease and prevent permanent blindness. However, receiving recurrent injections can potentiall…
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Coutinho da Silva, Marco; Lannutti, John; Ohr, Matthew; Swindle-Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

miRNA Biomarkers for Diagnosis and Prediction of Radiation Induced Injury
TS-041968 — A minimally invasive procedure to determine radiation toxicity in victims of nuclear events or radiation therapy patients.
The lack of a reliable radiation biodosimeter has been a major barrier to medical decision-making regarding the triage and treatment of persons - civilians, soldiers and first-time responders - who might be at risk for developing acute radiation syndromes (ARS) following nuclear events (e.g. nucle…
  • College: College of Medicine (COM)
  • Inventors: Jacob, Naduparambil "Naduparambil"
  • Licensing Officer: Norris, Francis "Frank"

miRNA Biomarkers for Diagnosis and Prediction of Radiation Induced Injury
TS-041968 — A minimally invasive procedure to determine radiation toxicity in victims of nuclear events or radiation therapy patients.
The lack of a reliable radiation biodosimeter has been a major barrier to medical decision-making regarding the triage and treatment of persons - civilians, soldiers and first-time responders - who might be at risk for developing acute radiation syndromes (ARS) following nuclear events (e.g. nucle…
  • College: College of Medicine (COM)
  • Inventors: Jacob, Naduparambil "Naduparambil"
  • Licensing Officer: Norris, Francis "Frank"

Junctional Tourniquet for Groin and Axillary Regions
TS-041808 — A tourniquet with a ratcheting lock to keep pressure on wounds in the groin and axillary regions. Hemostasis can be achieved while the patient is still in the field.
Patients with blood loss in the field need to be treated immediately to prevent ongoing blood loss, shock, and death; bleeding from extremity and junctional wounds is the leading cause of potentially preventable death from penetrating injuries. Direct manual pressure is effective for the initial c…
  • College: OSU Wexner Medical Center
  • Inventors: McElroy, James; Graham, Nadi; Nocera, Tanya
  • Licensing Officer: Flammang, Ann Marie

Papaverine Derivatives that are Effective Hypoxic Tumor Radiosensitizers
TS-041504 — Dr. Nicholas Denko and colleagues at The Ohio State University have developed papaverine derivatives that can be used as metabolic radiosensitizers in hypoxic tumors. The compounds make cancer cells more sensitive to radiation therapy without the concomitant toxicity issues that can occur as a side-effect of papaverine.
Radiation therapy is a common treatment for cancerous tumors. However, environmental conditions in the tumor can influence sensitivity to radiation therapy, and some cells are resistant to treatment. For example, hypoxic cells (those with low levels of oxygen) in tumors such as lung, glioblastoma,…
  • College: College of Medicine (COM)
  • Inventors: Denko, Nicholas; Benej, Martin; Mitton-Fry, Mark; Papandreou, Ioanna; Vibhute, Sandip
  • Licensing Officer: Davis, Stewart

Multifunctional RNA Nanoparticles and Methods for Treating Cancer
TS-040289 — Three-way junction nanoparticles for delivery of tamoxifen and other therapeutics directly to tumor cells.
Most breast cancers express estrogen receptor alpha (ER α) and antagonists of ER α drugs, such as tamoxifen, have been widely used for their treatment. Unfortunately, up to half of all ER α -positive tumors have intrinsic or acquired endocrine therapy resistance. Recent studies b…
  • College: College of Pharmacy
  • Inventors: Zhang, Xiaoting; Guo, Peixuan
  • Licensing Officer: Flammang, Ann Marie

Show More Technologies

Loading icon